<DOC>
	<DOCNO>NCT00261846</DOCNO>
	<brief_summary>This open-label , continuous daily dosing , two-part safety efficacy study SKI-606 ( bosutinib ) Philadelphia chromosome positive leukemia ( Ph+ ) . Part 1 dose-escalation study chronic phase Chronic Myelogenous Leukemia ( CML ) subject establish maximum tolerate dose ( MTD ) subject population . Part 2 begin completion Part 1 dose establish compound chronic phase subject . Part 2 study efficacy 500mg daily oral SKI-606 ( bosutinib ) patient phase Ph+ CML Ph+ Acute Lymphocytic Leukemia ( ALL ) . The protocol test hypotheses oral daily dose bosutinib 500 mg attain ( 1 ) Major Cytogenetic Response ( MCyR ) chronic phase CML patient ( 2 ) Overall Hematological Response ( OHR ) advance leukemia patient . Each phase disease evaluate separate cohort .</brief_summary>
	<brief_title>Study Evaluating SKI-606 ( Bosutinib ) In Philadelphia Chromosome Positive Leukemias</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>Ph+ CML Ph+ ALL primarily refractory fulldose imatinib ( 600 mg ) , disease progression/relapse fulldose imatinib , intolerant dose imatinib . At least 3 month post stem cell transplantation Able take daily oral capsules/tablets reliably Subjects Philadelphia chromosome , bcrabl negative CML Overt leptomeningeal leukemia Subjects without evidence leukemia bone marrow ( extramedullary disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>philadelphia chromosome</keyword>
	<keyword>Myeloid</keyword>
	<keyword>Philadelphia Positive</keyword>
</DOC>